Shares of ChromaDex Corp. (OTCBB: CDXC.OB) jumped up briefly to $1.34 before settling at $1.23 per share on moderate volume. ChromaDex announced a net loss attributable to common stockholders of $0.01 per share for the thirteen week period ended July 3, 2010 and top-line revenues of $2.03 million compared to $1.34 million in the year ago quarter.
As of July 3, 2010, cash, cash equivalents, and marketable securities totaled $3,381,744.
"ChromaDex is continuing to position ourselves to take advantage of the unique product offerings we have acquired and will continue to develop novel ingredients for dietary supplement, food and related industries," said Frank Jaksch, CEO and co-founder of ChromaDex. "By continuing to license technology that ChromaDex believes has a strong future potential to be marketed to many industry segments, we will be able to offer our customers and consumers significant new options in the field of natural products."
On a reported basis, ChromaDex recorded revenue during the second quarter of 2010 of $2,033,861 as compared to $1,342,716 for the same period in 2009. The net loss attributable to common stockholders for the thirteen weeks ended July 3, 2010, was $303,529 as compared to a net loss of $291,100 for the same period in 2009. The net loss in the second quarter of 2010 was attributable an increase in share based compensation expenses of $230,858 as compared to a $50,830 versus the same period in 2009, and an adoption of a formal investor relations program to increase market and shareholder awareness.
ChromaDex is a leader in the development of phytochemical and botanical reference standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the novel ingredients, analytical tools and services to meet product regulatory, quality, efficacy and safety standards.
No comments:
Post a Comment